[go: up one dir, main page]

WO2003028647A3 - Identification of genes involved in restenosis and in atherosclerosis - Google Patents

Identification of genes involved in restenosis and in atherosclerosis Download PDF

Info

Publication number
WO2003028647A3
WO2003028647A3 PCT/US2002/031216 US0231216W WO03028647A3 WO 2003028647 A3 WO2003028647 A3 WO 2003028647A3 US 0231216 W US0231216 W US 0231216W WO 03028647 A3 WO03028647 A3 WO 03028647A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
restenosis
identification
genes involved
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/031216
Other languages
French (fr)
Other versions
WO2003028647A2 (en
Inventor
Stephen E Epstein
Sarfraz Durrani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedStar Research Institute
Original Assignee
MedStar Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedStar Research Institute filed Critical MedStar Research Institute
Priority to CA002462573A priority Critical patent/CA2462573A1/en
Priority to US10/491,428 priority patent/US20040265829A1/en
Priority to EP02766440A priority patent/EP1451347A2/en
Priority to KR10-2004-7004880A priority patent/KR20040068115A/en
Publication of WO2003028647A2 publication Critical patent/WO2003028647A2/en
Publication of WO2003028647A3 publication Critical patent/WO2003028647A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods are provided for estimating the risk of developing restenosis or of atherosclerosis in an individual. Methods and compositions for treating or preventing restenosis or atherosclerosis also are provided.
PCT/US2002/031216 2001-10-02 2002-10-02 Identification of genes involved in restenosis and in atherosclerosis Ceased WO2003028647A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002462573A CA2462573A1 (en) 2001-10-02 2002-10-02 Identification of genes involved in restenosis and in atherosclerosis
US10/491,428 US20040265829A1 (en) 2001-10-02 2002-10-02 Identification of genes involved in restenosis and in atherosclerosis
EP02766440A EP1451347A2 (en) 2001-10-02 2002-10-02 Identification of genes involved in restenosis and in atherosclerosis
KR10-2004-7004880A KR20040068115A (en) 2001-10-02 2002-10-02 Identification of genes involved in restenosis and in atherosclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32621001P 2001-10-02 2001-10-02
US60/326,210 2001-10-02

Publications (2)

Publication Number Publication Date
WO2003028647A2 WO2003028647A2 (en) 2003-04-10
WO2003028647A3 true WO2003028647A3 (en) 2003-07-24

Family

ID=23271269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031216 Ceased WO2003028647A2 (en) 2001-10-02 2002-10-02 Identification of genes involved in restenosis and in atherosclerosis

Country Status (6)

Country Link
US (2) US20040265829A1 (en)
EP (1) EP1451347A2 (en)
KR (1) KR20040068115A (en)
CN (1) CN1599799A (en)
CA (1) CA2462573A1 (en)
WO (1) WO2003028647A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071437A2 (en) * 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
WO2007111626A2 (en) * 2006-03-23 2007-10-04 The Johns Hopkins University Arginase ii: a target for the prevention and treatment of atherosclerosis
CN108753943A (en) * 2018-01-17 2018-11-06 中国医学科学院阜外医院 The application of miR-216a and its target gene in vascular ageing and atherosclerotic heart disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024604A1 (en) * 1995-02-10 1996-08-15 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024604A1 (en) * 1995-02-10 1996-08-15 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUTIERI ET AL.: "Use of differential display of identify differentially expressed mRNAs induced by rat carotid artery balloon angioplasty", LABORATORY INVESTIGATION, vol. 72, no. 6, 1995, pages 656 - 661, XP001088486 *
FELDMAN ET AL.: "Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit", CIRCULATION, vol. 103, June 2001 (2001-06-01), pages 3117 - 3122, XP002963853 *
KHARE ET AL.: "Differential regulation of somatostatin receptor type 1-5 in rat aorta after angioplasty", FASEB J., vol. 13, 1999, pages 387 - 394, XP000945354 *
NIKOL ET AL.: "Differential expression of nonmuscle myosin II isoforms in human atherosclerotic plaque", ATHEROSCLEROSIS, vol. 130, 1997, pages 71 - 85, XP002963854 *
WU ET AL.: "Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 6, 2000, pages 433 - 440, XP008010068 *

Also Published As

Publication number Publication date
US20030170673A1 (en) 2003-09-11
EP1451347A2 (en) 2004-09-01
CN1599799A (en) 2005-03-23
CA2462573A1 (en) 2003-04-10
US20040265829A1 (en) 2004-12-30
WO2003028647A2 (en) 2003-04-10
KR20040068115A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
WO2001031580A3 (en) Methods and devices for identifying patterns in biological systems
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO1999025690A3 (en) Advanced glycation end-product intermediaries and post-amadori inhibition
AU2003225355A1 (en) System and method for investing illiquid or restricted assets
GB2397971A8 (en) Method for routing electronic correspondance based on the level and type of emotion contained therein
AU2002314417A1 (en) Identification and characterization of plant genes
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
AU2003243606A1 (en) System and method for purchasing lottery tickets
EP1423531A4 (en) Compositions and methods for the inference of pigmentation traits
AU2002360679A1 (en) Card game and method of playing the same
AU5294100A (en) Method and compositions for treating the inflammatory response
AU2002244582A1 (en) Anonymous payment system and method
AU2002223287A1 (en) Method and system for online purchasing
NO20012095D0 (en) Compositions and Methods for Preparing Dispersions and Methods for Using the Dispersions
AU2002364277A8 (en) Method for the assessment and prognosis of sarcoidosis
WO2001031579A3 (en) Methods and devices for identifying patterns in biological patterns
AU2003262946A1 (en) Method of preventing or treating atherosclerosis or restenosis
ZA200203253B (en) Methods and kits for treating depression or preventing deterioration of cognitive function.
EP1575567A4 (en) Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
AU2001255222A1 (en) Method of and system for effecting anonymous credit card purchases over the internet
AU7076000A (en) An online purchase system and method
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2003028647A3 (en) Identification of genes involved in restenosis and in atherosclerosis
WO2003014988A8 (en) System and method for providing real time pricing based on variables
ZA200203435B (en) Method and compositions for treating pulmonary diseases.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002330176

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2462573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047004880

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002766440

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028241924

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10491428

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002766440

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002766440

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP